Greenwich LifeSciences, Inc. (NASDAQ: GLSI) is a Healthcare company (Biotechnology) with a market capitalization of $241M. The Maz Rating grades it against the other companies in its sector.
Greenwich LifeSciences, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
Greenwich LifeSciences, Inc. has been loss-making over the last twelve months, so it has no meaningful P/E. It runs a gross margin of 0.0%, an operating margin of 0.0% and a net margin of 0.0%. It shows return on equity of -1335.1%, return on invested capital of 1348.3% and a free cash flow yield of -6.3%. On the balance sheet: a debt-to-equity ratio of 0.00 and a current ratio of 0.77. Over the past 52 weeks the share price ranged from $7.78 to $34.10, with a beta of 1.55.
Greenwich LifeSciences, Inc. does not currently pay a dividend.
2 Wall Street analyst ratings cover the stock: 2 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Greenwich LifeSciences, Inc. functions as a clinical-stage biopharmaceutical company, dedicated to developing innovative cancer immunotherapies. These treatments are primarily focused on breast cancer and other HER2/neu-positive malignancies. Its flagship therapeutic candidate is GP2, an immunotherapy which has successfully completed its Phase IIb clinical trials. This drug is designed to prevent the recurrence of breast cancer in patients who have already undergone surgical removal of the tumor. Founded in 2006 and based in Stafford, Texas, the company was formerly known as Norwell, Inc. until it rebranded to Greenwich LifeSciences, Inc. in March 2018.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Greenwich LifeSciences, Inc. (GLSI) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 2.43% / 30% · Interest income / Revenue 4696600.0% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 2.43% / 33% · Receivables / Mkt Cap (36m) 0.00% / 49% · Interest income / Revenue 4696600.0% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 2.43% / 33.33% · Receivables / Mkt Cap (24m) 0.00% / 33.33% · Interest income / Revenue 4696600.0% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 0.00% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 100.0% / 33.33% · Receivables / Avg Assets (4Q) 0.00% / 33.33% · Interest income / Revenue 4696600.0% / 5% | Fail |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 100.0% / 33.33% · (Cash+Recv) / Total Assets 100.0% / 33.33% · Interest income / Revenue 4696600.0% / 5% | Fail |
No. As of September 2026, Greenwich LifeSciences, Inc. (GLSI) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Greenwich LifeSciences, Inc. is over the AAOIFI limit on Interest income / Revenue.
About 4696600.0% of each dividend: Greenwich LifeSciences, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.